Hormonal circadian rhythms in patients with congenital adrenal hyperplasia: identifying optimal monitoring times and novel disease biomarkers
Open accessThe DOI matches its Crossref record; 42 of the 47 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: The treatment goal in congenital adrenal hyperplasia (CAH) is to replace glucocorticoids while avoiding androgen excess and iatrogenic Cushing's syndrome. However, there is no consensus on how to monitor disease control. Our main objectives were to evaluate hormonal circadian rhythms and use these profiles to identify optimal monitoring times and novel disease biomarkers in CAH adults on intermediate- and long-acting glucocorticoids. DESIGN: This was an observational, cross-sectional study at the National Institutes of Health Clinical Center in 16 patients with classic CAH. METHODS: Twenty-four-hour serum sampling for ACTH, 17-hydroxyprogesterone (17OHP), androstenedione (A4), androsterone, DHEA, testosterone, progesterone and 24-h urinary pdiol and 5β-pdiol was carried out. Bayesian spectral analysis and cosinor analysis were performed to detect circadian rhythmicity. The number of hours to minimal (TminAC) and maximal (TmaxAC) adrenocortical hormone levels after dose administration was calculated. RESULTS: A significant rhythm was confirmed for ACTH (r(2), 0.95; P<0.001), 17OHP (r(2), 0.70; P=0.003), androstenedione (r(2), 0.47; P=0.043), androsterone (r(2), 0.80; P<0.001), testosterone (r(2), 0.47; P=0.042) and progesterone (r(2), 0.64; P=0.006). The mean (s.d.) TminAC and TmaxAC for 17OHP and A4 were: morning prednisone (4.3 (2.3) and 9.7 (3.5) h), evening prednisone (4.5 (2.0) and 10.3 (2.4) h), and daily dexamethasone (9.2 (3.5) and 16.4 (7.2) h). AUC0-24 h progesterone, androsterone and 24-h urine pdiol were significantly related to 17OHP. CONCLUSION: In CAH patients, adrenal androgens exhibit circadian rhythms influenced by glucocorticoid replacement. Measurement of adrenocortical hormones and interpretation of results should take into account the type of glucocorticoid and time of dose administration. Progesterone and backdoor metabolites may provide alternative disease biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Circadian rhythm and the timing of GC intake influence steroid measurements (223).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [223]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Self-citationCornelissen, G. (2014) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-11-16 · Cited by 811
Congenital adrenal hyperplasia
El-Maouche, D., Arlt, W., & Merke, D. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31431-9 · Cited by 669
Self-citationCongenital adrenal hyperplasia.
Merke, D. P., & Bornstein, S. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66736-0 · Cited by 628
Self-citationHealth status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients
Arlt, W., Willis, D. S., Wild, S. H., Krone, N., Doherty, E. J., Hahner, S., Han, T. S., Carroll, P. V., Conway, G. S., Rees, D. A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0917 · Cited by 506
Self-citationBayesian Spectrum Analysis and Parameter Estimation
Guber, M. H. J. (1990) · Technometrics · doi:10.1080/00401706.1990.10484646 · Cited by 440
Bayesian Spectrum Analysis and Parameter Estimation
Bretthorst, G. L. (1988) · Lecture Notes in Statistics · doi:10.1007/978-1-4684-9399-3 · Cited by 428
Congenital Adrenal Hyperplasia: Is there an Effect on Penile Growth?
Levy, J. B., & Husmann, D. A. (1996) · The Journal of Urology · doi:10.1097/00005392-199608001-00060 · Cited by 415
The backdoor pathway to dihydrotestosterone
Auchus, R. J. (2004) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2004.09.004 · Cited by 347
Potency and duration of action of glucocorticoids
Meikle, A. W., & Tyler, F. H. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90233-9 · Cited by 319
Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia
Finkielstain, G. P., Kim, M. S., Sinaii, N., Nishitani, M., Van Ryzin, C., Hill, S. C., Reynolds, J. C., Hanna, R. M., & Merke, D. P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2102 · Cited by 313
Self-citationAdrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency.
Merke, D. P., Chrousos, G. P., Eisenhofer, G., Weise, M., Keil, M. F., Rogol, A. D., Van Wyk, J. J., & Bornstein, S. R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431903 · Cited by 266
Self-citationGuo, T., Taylor, R. L., Singh, R. J., & Soldin, S. J. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2006.03.034 · Cited by 227
Self-citationVELDHUIS, J. D., IRANMANESH, A., JOHNSON, M. L., & LIZARRALDE, G. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-2-452 · Cited by 205
Finkielstain, G. P., Chen, W., Mehta, S. P., Fujimura, F. K., Hanna, R. M., Van Ryzin, C., McDonnell, N. B., & Merke, D. P. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0319 · Cited by 192
Self-citationKamrath, C., Hochberg, Z., Hartmann, M. F., Remer, T., & Wudy, S. A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1997 · Cited by 191
Approach to the patient: the adult with congenital adrenal hyperplasia
Auchus, R. J., & Arlt, W. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1440 · Cited by 121 · cited 1×
“European Journal of Endocrinology, 173 (6).”
Nonclassic Congenital Adrenal Hyperplasia
Witchel, S. F., & Azziz, R. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/625105 · Cited by 101
Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency
Auchus, R. J., Buschur, E. O., Chang, A. Y., Hammer, G. D., Ramm, C., Madrigal, D., Wang, G., Gonzalez, M., Xu, X. S., Smit, J. W., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1258 · Cited by 97
Kinetics and Interconversion of Prednisolone and Prednisone Studied with New Radioimmunoassays
MEIKLE, A. W., WEED, J. A., & TYLER, F. H. (1975) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-41-4-717 · Cited by 87
Charmandari, E. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.10.4679 · Cited by 84
Bone mineral density, bone markers, and fractures in adult males with congenital adrenal hyperplasia
Falhammar, H., Filipsson Nyström, H., Wedell, A., Brismar, K., & Thorén, M. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0865 · Cited by 82
Topor, L. S., Asai, M., Dunn, J., & Majzoub, J. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0692 · Cited by 57
Frisch, H., Parth, K., Schober, E., & Swoboda, W. (1981) · Archives of Disease in Childhood · doi:10.1136/adc.56.3.208 · Cited by 56 · cited 1×
“Briefly, 1 mL aliquots of urine were treated with エglucuronidase (Type VII-A, Sigma), followed by addition of an internal standard ( 13C(3) 17hydroxyprogesterone).”
El‐Maouche, D., Collier, S., Prasad, M., Reynolds, J. C., & Merke, D. P. (2015) · Clinical Endocrinology · doi:10.1111/cen.12507 · Cited by 53
Self-citationBachelot, A., Chakhtoura, Z., Plu-Bureau, G., Coudert, M., Coussieu, C., Badachi, Y., Dulon, J., Charbit, B., & Touraine, P. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0454 · Cited by 53
Groschl, M. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.3.1200 · Cited by 51
170H-progesterone rhythms in congenital adrenal hyperplasia.
Young, M. C., Robinson, J. A., Read, G. F., Riad-Fahmy, D., & Hughes, I. A. (1988) · Archives of Disease in Childhood · doi:10.1136/adc.63.6.617 · Cited by 47
Bioavailability and pharmacokinetics of prednisone in humans
DiSanto, A. R., & DESANTE, K. A. (1975) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600640122 · Cited by 39
Rivkees, S. A. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/569680 · Cited by 31
Hughes, I. A., & Read, G. F. (2008) · Hormone Research · doi:10.1159/000179870 · Cited by 31
Völkl, T. M. K., Öhl, L., Rauh, M., Schöfl, C., & Dörr, H. G. (2011) · Hormone Research in Paediatrics · doi:10.1159/000333696 · Cited by 29
Androgen Synthesis in Patients with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency
Kamrath, C., Hartmann, M., & Wudy, S. (2013) · Hormone and Metabolic Research · doi:10.1055/s-0032-1331751 · Cited by 25
And, P. M., & LONDON, D. R. (1982) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1982.tb01627.x · Cited by 23
Duration of Suppression of Adrenal Steroids after Glucocorticoid Administration
Fuqua, J. S., Rotenstein, D., & Lee, P. A. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/712549 · Cited by 22
AN ACTH‐SECRETING PITUITARY TUMOUR ARISING IN A PATIENT WITH CONGENITAL ADRENAL HYPERPLASIA
Horrocks, P. M., Franks, S., Hockley, A. D., Rolfe, E. B., Noorden, S. V., & LONDON, D. R. (1982) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1982.tb01613.x · Cited by 21
Chronobiology: principles and methods.
Cugini, P. (1993) · PubMed · Cited by 21
The pharmacokinetics of low-dose dexamethasone in congenital adrenal hyperplasia
Young, M. C., Cook, N., Read, G. F., & Hughes, I. A. (1989) · European Journal of Clinical Pharmacology · doi:10.1007/bf00609429 · Cited by 19
Sólyom, J. (1984) · Archives of Disease in Childhood · doi:10.1136/adc.59.8.743 · Cited by 19
Exploring fMRI data for periodic signal components
Hansen, L. K., Nielsen, F. Å., & Larsen, J. O. (2002) · Artificial Intelligence in Medicine · doi:10.1016/s0933-3657(02)00007-6 · Cited by 17
Krakamp, B., Tanswell, P., Vogel, H., & Bozler, G. (1989) · European Journal of Clinical Pharmacology · doi:10.1007/bf00561028 · Cited by 14
Dauber, A. N., Feldman, H. A., & Majzoub, J. A. (2010) · International Journal of Pediatric Endocrinology · doi:10.1155/2010/347636 · Cited by 12
Cited by
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Self-citationCongenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Self-citationManagement challenges and therapeutic advances in congenital adrenal hyperplasia
Mallappa, A., & Merke, D. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00655-w · Cited by 113
Self-citationModified-Release Hydrocortisone in Congenital Adrenal Hyperplasia
Merke, D. P., Mallappa, A., Arlt, W., Brac de la Perriere, A., Lindén Hirschberg, A., Juul, A., Newell-Price, J., Perry, C. G., Prete, A., Rees, D. A., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab051 · Cited by 109
“In 21-OHD-CAH, the physiological pathway to androstenedione biosynthesis from 17hydroxypregenolone via DHEA is downregulated (43,44), and androstenedione biosynthesis primarily occurs through conversion of excess 17OHP.”
BackgroundSelf-citationNella, A. A., Mallappa, A., Perritt, A. F., Gounden, V., Kumar, P., Sinaii, N., Daley, L.-A., Ling, A., Liu, C.-Y., Soldin, S. J., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1916 · Cited by 91
Self-citation
Metadata
- Authors
- Debono, M., Mallappa, A., Gounden, V., Nella, A. A., Harrison, R. F., Crutchfield, C. A., Backlund, P. S., Soldin, S. J., Ross, R. J., & Merke, D. P.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Debono, Miguel
- ORCID
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-12
- Volume
- 173
- Issue
- 6
- Pages
- 727-737
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- PMC
- PMC4623929
- OpenAlex
- W2114612506
- Cited by
- 53
- References
- 47
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 5 · 2023: 5 · 2022: 7 · 2021: 11 · 2020: 4 · 2019: 4 · 2018: 4 · 2017: 3 · 2016: 2 · 2015: 1
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute for Health and Care Research (CL-2013-04-001, BRF-2011-005)
- National Institutes of Health (Z99CL999999)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- congenital adrenal hyperplasia, circadian rhythm, glucocorticoid replacement therapy, 17-hydroxyprogesterone, ACTH, androsterone, androstenedione, adrenal androgens, disease surveillance, disease biomarkers, prednisone, dexamethasone, cosinor analysis
- MeSH terms
- Adrenal Hyperplasia, Congenital, Adrenocorticotropic Hormone, Adult, Androstenedione, Androsterone, Circadian Rhythm, Cross-Sectional Studies, Dehydroepiandrosterone, Dexamethasone, Female, Glucocorticoids, Hormones, Humans, Male, Prednisone, Pregnanediones, Progesterone, Testosterone, Biomarkers, 17-alpha-Hydroxyprogesterone, 5-alpha-Dihydroprogesterone, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.